ARS Pharmaceuticals, Inc. SPRY Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s total debt?
- ARS Pharmaceuticals, Inc. (SPRY) reported total debt of $96.52M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s total debt changed year-over-year?
- ARS Pharmaceuticals, Inc.'s total debt increased by 132121.9% year-over-year, from $73K to $96.52M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s total debt?
- Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s total debt has grown at a 97.3% compound annual growth rate (CAGR), from $3.22M to $96.37M.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.